R. Heist

发表

Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2011, Science Translational Medicine.

No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis.

R. Booton, C. Tibaldi, D. Christiani, 2011, Lung cancer.

Code Status Documentation in the Outpatient Electronic Medical Records of Patients with Metastatic Cancer

R. Heist, J. Temel, J. Greer, 2010, Journal of General Internal Medicine.

Polymorphisms of Vitamin D Receptor and Survival in Early-Stage Non–Small Cell Lung Cancer Patients

D. Neuberg, E. Giovannucci, D. Christiani, 2006, Cancer Epidemiology Biomarkers & Prevention.

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.

S. Digumarthy, L. Sequist, A. Shaw, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma

N. Nishioka, D. Christiani, R. Heist, 2008, British Journal of Cancer.

Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): Survival and clinical activity by subgroup analysis.

David C. Smith, L. Sequist, F. Hodi, 2014 .

Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.

S. Digumarthy, A. Iafrate, C. Channick, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients.

D. Neuberg, E. Giovannucci, D. Christiani, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Atezolizumab (atezo) plus platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): Update from a phase Ib study.

G. Giaccone, F. Hodi, S. Gettinger, 2017 .

Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancer

S. Gettinger, R. Heist, M. Hellmann, 2020, International Journal of Cancer.

MA16.09 Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

Jeffrey W. Clark, A. Drilon, M. Socinski, 2017 .

NCCN Small Cell Lung Cancer Clinical Practice Guidelines in Oncology

C. Rudin, R. Govindan, B. Loo, 2013 .

ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA.

H. Groen, G. Scagliotti, N. Hanna, 2022, European journal of cancer.

VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.

Xihong Lin, D. Christiani, R. Heist, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second Hand Smoke Exposure and Survival in Early-Stage Non–Small-Cell Lung Cancer Patients

D. Neuberg, D. Christiani, R. Heist, 2006, Clinical Cancer Research.

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

M. Kris, V. Rusch, C. Azzoli, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Matrix Metalloproteinase Polymorphisms and Survival in Stage I Non–Small Cell Lung Cancer

D. Neuberg, D. Christiani, R. Heist, 2006, Clinical Cancer Research.

Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non–Small Cell Lung Cancer

Xihong Lin, D. Christiani, R. Heist, 2008, Clinical Cancer Research.

Brief Report of Biweekly Pemetrexed and Gemcitabine in Elderly Patients with Non-small Cell Lung Cancer

L. Sequist, P. Fidias, R. Heist, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.

H. Shih, R. Heist, H. Willers, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.

S. Digumarthy, A. Iafrate, L. Chirieac, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients.

D. Neuberg, D. Christiani, R. Heist, 2006, Lung cancer.

Abstract CT077: Five-year follow-up from the CA209-003 study of nivolumab in previously treated advanced non-small cell lung cancer (NSCLC): Clinical characteristics of long-term survivors

David C. Smith, L. Sequist, S. Gettinger, 2017 .

A single‐nucleotide polymorphism in the methylene tetrahydrofolate reductase (MTHFR) gene is associated with risk of radiation pneumonitis in lung cancer patients treated with thoracic radiation therapy

A. Niemierko, R. Mak, D. Christiani, 2012, Cancer.

Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis.

D. Christiani, R. Heist, R. Zhai, 2009, Carcinogenesis.

Small Cell Lung Cancer − Gender , and the Risk of Non Vascular Endothelial Growth Factor Genotypes , Haplotypes ,

Xihong Lin, D. Christiani, R. Heist, 2008 .

Long-term Survival, Clinical Activity, and Safety of Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) in Patients (Pts) With Advanced Non-Small Cell Lung Cancer (NSCLC)

David C. Smith, L. Sequist, F. Hodi, 2014 .

Depression and survival in metastatic non-small-cell lung cancer: effects of early palliative care.

L. Traeger, R. Heist, J. Temel, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The SELECT study: A multicenter phase II trial of adjuvant erlotinib in resected epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).

C. Azzoli, P. Jänne, R. Govindan, 2012 .

Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

S. Gettinger, R. Heist, Gregory Riely, 2022, JTO clinical and research reports.

p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.

D. Cescon, D. Christiani, R. Heist, 2010, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer.

D. Neuberg, E. Giovannucci, D. Christiani, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Title: A Randomized, Controlled Trial of Integrated vs. Standard Palliative Care in Patients with Advanced NSCLC

E. Lamont, L. Sequist, L. Traeger, 2008 .

Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer.

H. Groen, T. Overbeck, Michael Thomas, 2020, The New England journal of medicine.

Association between Polymorphisms in Cancer-Related Genes and Early Onset of Esophageal Adenocarcinoma 1,2,3

F. Chen, R. Heist, R. Zhai, 2011 .

Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

H. Groen, E. Smit, R. Heist, 2019, Journal of Clinical Oncology.

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

M. Socinski, R. Heist, E. Vokes, 2015 .

Safety and efficacy of combination olaparib (O) and temozolomide (T) in small cell lung cancer (SCLC).

C. Azzoli, M. Mino‐Kenudson, D. Haber, 2018 .

AB065. P-36. Debio 1347 in patients with cholangiocarcinoma harboring an FGFR gene alteration: preliminary results

K. Flaherty, M. Voss, G. Iyer, 2019, Hepatobiliary surgery and nutrition.

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib

A. Shaw, R. Heist, A. Muzikansky, 2022, JTO clinical and research reports.

441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2016 .

LKB1 loss rewires JNK-induced apoptotic protein dynamics through NUAKs and sensitizes KRAS-mutant NSCLC to combined KRASG12C + MCL-1 blockade

R. Heist, W. Haas, R. Morris, 2022, bioRxiv.

Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLC

M. Mino‐Kenudson, L. Sequist, R. Heist, 2022, JTO clinical and research reports.

SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC.

M. Kris, C. Azzoli, P. Jänne, 2014 .

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016 .

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.

Lauren L. Ritterhouse, G. Getz, S. Digumarthy, 2016, Cancer discovery.

Phase II Study of Lorlatinib in Patients With Anaplastic Lymphoma Kinase–Positive Lung Cancer and CNS-Specific Relapse

S. Digumarthy, A. Shaw, R. Heist, 2022, JCO precision oncology.

Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein–Expressing Non–Small-Cell Lung Cancer

R. Heist, K. Kelly, E. Vokes, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary clinical pharmacokinetics and pharmacodynamics of Debio 1347 (CH5183284), a novel FGFR inhibitor.

M. Voss, R. Heist, J. Supko, 2015 .

Implementation and Clinical Adoption of Precision Oncology Workflows Across a Healthcare Network

Jeffrey W. Clark, Lauren L. Ritterhouse, M. Rivera, 2022, The oncologist.

Small Cell Lung Cancer

C. Rudin, R. Govindan, R. Heist, 2016, Seminars in Respiratory and Critical Care Medicine.

Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: Results from the GEOMETRY mono-1 study.

H. Groen, R. Heist, J. Wolf, 2022, European journal of cancer.

Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.

R. Heist, J. Temel, A. Muzikansky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

P. Jänne, R. Heist, J. Christensen, 2022, The New England journal of medicine.

SnapShot: non-small cell lung cancer.

J. Engelman, R. Heist, 2012, Cancer cell.

Association between polymorphisms in cancer-related genes and early onset of esophageal adenocarcinoma.

D. Christiani, R. Heist, R. Zhai, 2011, Neoplasia.

A Large-scale genetic association study of esophageal adenocarcinoma risk.

Feng Chen, David C Christiani, Michael C Wu, 2010, Carcinogenesis.

Inconsistency and features of single nucleotide variants detected in whole exome sequencing versus transcriptome sequencing: A case study in lung cancer.

Junfeng Xia, Peilin Jia, William Pao, 2015, Methods.

Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms.

M. Mino‐Kenudson, L. Sequist, J. Engelman, 2021, Cancer cell.

Lung cancer

L. Sequist, R. Heist, B. Solomon, 2021, The Lancet.

p53 Arg72Pro and MDM2 T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis

D. Cescon, D. Christiani, R. Heist, 2009, Clinical Cancer Research.

Detection of Novel Actionable Genetic Changes in Salivary Duct Carcinoma Helps Direct Patient Treatment

Julie M. Batten, A. Iafrate, K. Flaherty, 2012, Clinical Cancer Research.

Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung

Maristela L Onozato, A. Iafrate, M. Onozato, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer

Hongbing Shen, Q. Wei, C. Amos, 2014, Cancer Epidemiology, Biomarkers & Prevention.

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

D. Ettinger, M. Kris, M. Socinski, 2017 .

Clinical acquired resistance to KRASG12C inhibition through a novel KRAS switch-II pocket mutation and polyclonal alterations converging on RAS-MAPK reactivation.

R. Heist, D. Juric, J. Lennerz, 2021, Cancer discovery.

Rociletinib in EGFR-mutated non-small-cell lung cancer.

J. Neal, H. Wakelee, L. Sequist, 2015, The New England journal of medicine.

Phase 1, open-label, dose-escalation and expansion study of ABBV-399, an antibody drug conjugate (ADC) targeting c-Met, in patients (pts) with advanced solid tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2016 .

Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.

S. Digumarthy, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: A case‐only study

Xihong Lin, R. Heist, J. Wain, 2012, Cancer.

Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.

F. Chen, D. Christiani, R. Heist, 2011, Carcinogenesis.

Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers.

A. Letai, Kwok-Kin Wong, M. Mino‐Kenudson, 2014, Cancer research.

Abstract LB002: Mechanisms of acquired resistance to KRAS G12C inhibition in cancer

P. Jänne, D. Root, R. Heist, 2021, Experimental and Molecular Therapeutics.

Genetic Changes in Squamous Cell Lung Cancer: A Review

L. Sequist, J. Engelman, R. Heist, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non–Small Cell Lung Cancer

A. Giobbie-Hurder, S. Digumarthy, H. Wakimoto, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody–Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non–Small Cell Lung Carcinoma

R. Heist, K. Kelly, E. Vokes, 2021, Clinical Cancer Research.

Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation

S. Digumarthy, R. Heist, J. Lennerz, 2021, Cancers.

Differential Outcomes in Codon 12/13 and Codon 61 NRAS-Mutated Cancers in the Phase II NCI-MATCH Trial of Binimetinib in Patients with NRAS-Mutated Tumors

R. Gray, K. Flaherty, L. Rubinstein, 2021, Clinical Cancer Research.

Clinicopathologic and Imaging Features of Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations

S. Digumarthy, R. Heist, J. Lennerz, 2019, Cancers.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Jeffrey W. Clark, L. Sequist, J. Engelman, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

MET Exon 14 Skipping in Non-Small Cell Lung Cancer.

Zhongming Zhao, A. Iafrate, P. Jia, 2016, The oncologist.

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

C. Rudin, P. Hammerman, R. Govindan, 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Wen Tan, Yang Zhao, David C Christiani, 2012, Clinical Cancer Research.

Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.

Xihong Lin, D. Christiani, R. Heist, 2008, Carcinogenesis.

Acquired Resistance to KRASG12C Inhibition in Cancer.

P. Jänne, D. Root, R. Heist, 2021, The New England journal of medicine.

MDM2 Promoter Polymorphism and Pancreatic Cancer Risk and Prognosis

D. Christiani, R. Heist, A. Zhu, 2008, Clinical Cancer Research.

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

David C. Smith, L. Sequist, S. Gettinger, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Mehmet Toner, Martin Peifer, Mari Mino-Kenudson, 2018, Cancer discovery.

Acquired Resistance to First‐Line Afatinib and the Challenges of Prearranged Progression Biopsies

L. Sequist, J. Engelman, P. Fidias, 2016, Journal of Thoracic Oncology.

Tumor Islands in Resected Early-stage Lung Adenocarcinomas are Associated With Unique Clinicopathologic and Molecular Characteristics and Worse Prognosis

Maristela L Onozato, Y. Yagi, A. Iafrate, 2013, The American journal of surgical pathology.

Tracking the Evolution of Resistance to ALK Tyrosine Kinase Inhibitors through Longitudinal Analysis of Circulating Tumor DNA.

Markus Riester, Cyril H Benes, S. Digumarthy, 2018, JCO precision oncology.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

M. Lawrence, A. Iafrate, M. Mino‐Kenudson, 2018, Cancer discovery.

Cigarette smoking increases copy number alterations in nonsmall-cell lung cancer

Xihong Lin, L. Chirieac, Kwok-Kin Wong, 2011, Proceedings of the National Academy of Sciences.

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2020 .

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

David C. Smith, J. Sosman, L. Sequist, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Genotyping lung cancer is an investment in the future.

E. Lamont, C. Azzoli, L. Sequist, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapeutics , Targets , and Chemical Biology Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Ef fi cacy of Combined MEK and PI 3 K Inhibitors for KRAS-Mutant Lung Cancers

A. Letai, Kwok-Kin Wong, M. Mino‐Kenudson, 2014 .

EGFR-targeted therapies in lung cancer: predictors of response and toxicity.

D. Christiani, R. Heist, 2009, Pharmacogenomics.

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib

D. Christiani, R. Heist, T. Lynch, 2008, The Pharmacogenomics Journal.

A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non–Small-Cell Lung Cancer

S. Digumarthy, J. Neal, L. Sequist, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

P. Jänne, S. Ou, R. Heist, 2021 .

KRYSTAL-2: A phase I/II trial of adagrasib (MRTX849) in combination with TNO155 in patients with advanced solid tumors with KRAS G12C mutation.

Xiaohong Yan, P. Jänne, A. Tolcher, 2021 .

Multidisciplinary management of small cell lung cancer.

R. Heist, H. Willers, S. Goldberg, 2013, Surgical oncology clinics of North America.

Small Cell Lung Cancer

C. Rudin, R. Govindan, B. Loo, 2022 .

Small Cell Lung CancerPractice Guidelines in Oncology

C. Rudin, R. Govindan, B. Loo, 2011 .

Exploration of Imaging Biomarkers for Predicting Survival of Patients With Advanced Non-Small Cell Lung Cancer Treated With Antiangiogenic Chemotherapy.

Koichi Hayano, Naveen M Kulkarni, D. Sahani, 2016, AJR. American journal of roentgenology.

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes

D. Christiani, R. Heist, J. Wain, 2009, Pharmacogenetics and genomics.

Vascular Endothelial Growth Factor Polymorphisms and Esophageal Cancer Prognosis

D. Christiani, R. Heist, J. Wain, 2009, Clinical Cancer Research.

Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non–Small Cell Lung Cancer

M. Mino‐Kenudson, L. Sequist, A. Shaw, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Improved tumor vascularization after anti-VEGF therapy with carboplatin and nab-paclitaxel associates with survival in lung cancer

Marek Ancukiewicz, Thomas J Lynch, Rakesh K Jain, 2015, Proceedings of the National Academy of Sciences.

Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer.

M. Lawrence, S. Digumarthy, M. Mino‐Kenudson, 2019, Cancer discovery.

Clinical Validation of a Cell-Free DNA Gene Panel.

Julie M. Batten, A. Iafrate, P. Brastianos, 2019, The Journal of molecular diagnostics : JMD.

Revisiting MET: Clinical Characteristics and Treatment Outcomes of Patients with Locally Advanced or Metastatic, MET-Amplified Esophagogastric Cancers.

Jeffrey W. Clark, A. Iafrate, C. Azzoli, 2020, The oncologist.

P. Hammerman, R. Heist, D. Costa, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

Mari Mino-Kenudson, David C Christiani, A. Iafrate, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Antitumor Activity of Crizotinib in Lung Cancers Harboring a MET Exon 14 Alteration

Jeffrey W. Clark, A. Drilon, R. Heist, 2019, Nature Medicine.

Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis.

Jeffrey W. Clark, A. Drilon, P. Jänne, 2019, Lung cancer.

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

R. Heist, D. Camidge, W. Messersmith, 2017, Clinical Cancer Research.

A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.

R. Heist, S. Dimitrijević, D. Camidge, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC

R. Heist, K. Kelly, E. Vokes, 2021, JTO clinical and research reports.

Palbociclib demonstrates intracranial activity in progressive brain metastases harboring cyclin-dependent kinase pathway alterations

A. Giobbie-Hurder, S. Carter, A. Iafrate, 2021, Nature Cancer.

Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors

Shanker Kalyana-Sundaram, A. Tolcher, R. Heist, 2020, Cancer Chemotherapy and Pharmacology.

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

M. Hidalgo, R. Heist, A. Schram, 2018, British Journal of Cancer.

First-in-Human Phase I, Dose-Escalation and -Expansion Study of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, in Patients With Advanced Solid Tumors.

J. Nemunaitis, R. Heist, K. Kelly, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions

C. Azzoli, L. Sequist, A. Shaw, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Cetuximab Monotherapy in Patients with Advanced Non-small Cell Lung Cancer After Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy

J. Neal, L. Sequist, P. Fidias, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Adjuvant therapy for a 3.9-cm adenocarcinoma of the lung.

C. Azzoli, R. Heist, 2013, The oncologist.

AdjuvantTherapyfora3.9-cmAdenocarcinomaoftheLung

C. Azzoli, R. Heist, 2013 .

Tumor epidermal growth factor receptor genotype and depression in stage IV non-small cell lung cancer.

L. Sequist, L. Traeger, R. Heist, 2011, The oncologist.

Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas

Jeffrey W. Clark, M. Mino‐Kenudson, R. Heist, 2020, Clinical Cancer Research.

A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations

A. Iafrate, K. Flaherty, J. Baselga, 2019, Clinical Cancer Research.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer.

T. Choueiri, R. Heist, M. Sznol, 2019, Cancer discovery.

Clinical Utility of Rapid EGFR Genotyping in Advanced Lung Cancer

Julie M. Batten, S. Digumarthy, A. Iafrate, 2018, JCO precision oncology.

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

B. Loo, R. Heist, J. Hayman, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

Association of MDM2 T309G and p53 Arg72Pro polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma

D. Cescon, R. Heist, R. Zhai, 2013, Journal of gastroenterology and hepatology.

A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies

D. Christiani, L. Sequist, P. Fidias, 2008, Cancer Epidemiology Biomarkers & Prevention.

MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.

D. Neuberg, L. Chirieac, D. Christiani, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

C. Ulrich, J. Cerhan, T. Sellers, 2013, Journal of the National Cancer Institute.

Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk

R. Heist, J. Wain, L. Su, 2008, International journal of cancer.

p53 Arg72Pro, MDM2 T309G, CCND1 G870A polymorphisms, histology and esophageal cancer prognosis

D. Cescon, D. Christiani, R. Heist, 2008 .

Prognostic significance of nuclear excision (NER) and base excision (BER) DNA repair gene polymorphisms in esophageal cancer

D. Christiani, R. Heist, T. Lynch, 2007 .

Capmatinib in MET exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

H. Groen, R. Heist, J. Wolf, 2021 .

Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).

S. Gettinger, R. Heist, S. Ou, 2018 .

Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan.

J. Berlin, A. Bardia, R. Heist, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Trop-2 as a therapeutic target for the antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132), in patients (pts) with previously treated metastatic small-cell lung cancer (mSCLC).

A. Bardia, R. Heist, D. Camidge, 2016 .

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non – Small-Cell Lung Cancer : Results From the CA 209-003 Study

David C. Smith, Julie, L. Sequist, 2018 .

Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk

D. Christiani, R. Heist, J. Wain, 2008, Cancer Causes & Control.

Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer.

G. Giaccone, F. Hodi, S. Gettinger, 2018, European journal of cancer.

Invasive adenocarcinoma of the lung is associated with the upper lung regions.

Raúl San José Estépar, G. Washko, E. Mark, 2014, Lung cancer.

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC).

H. Groen, E. Smit, R. Heist, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, M. Sznol, 2019 .

Safety and efficacy of the selective FGFR inhibitor debio 1347 in phase I study patients with FGFR genomically activated advanced biliary tract cancer (BTC).

K. Flaherty, J. Baselga, M. Voss, 2018 .

High-Dose Osimertinib for CNS Progression in EGFR+ NSCLC: A Multi-Institutional Experience

J. Neal, H. Wakelee, L. Sequist, 2022, JTO clinical and research reports.

A phase 2 clinical trial of the heat shock protein 90 (HSP 90) inhibitor ganetespib in patients with refractory advanced esophagogastric cancer

Jeffrey W. Clark, W. Goessling, R. Heist, 2020, Investigational New Drugs.

Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma.

Xihong Lin, N. Nishioka, F. Chen, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.

L. Sequist, D. Dias-Santagata, R. Heist, 2013, The Annals of thoracic surgery.

Genome-wide analysis of survival in early-stage non-small-cell lung cancer.

David C Christiani, Michael C Wu, Xihong Lin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

R. Heist, F. Meric-Bernstam, K. Yoh, 2021, Journal of Thoracic Oncology.

Results of the phase 1b study of ABBV-399 (telisotuzumab vedotin; teliso-v) in combination with erlotinib in patients with c-Met+ non-small cell lung cancer by EGFR mutation status.

R. Heist, K. Kelly, E. Vokes, 2019, Journal of Clinical Oncology.

A phase II study of gefitinib in patients with advanced thyroid cancer.

Thomas J Lynch, R. Heist, J. Temel, 2008, Thyroid : official journal of the American Thyroid Association.

The Prognostic Impact of KRAS, Its Codon and Amino Acid Specific Mutations, on Survival in Resected Stage I Lung Adenocarcinoma

A. Iafrate, C. Azzoli, Haiyu Zhou, 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors

R. Heist, B. C. Cho, Dong-Wan Kim, 2022, Investigational New Drugs.

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

O2-1 Datopotamab Deruxtecan (Dato-DXd; DS-1062), a TROP2 ADC, in patients with advanced NSCLC: Updated results of TROPION-PanTumor01 phase 1 study*

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021, Annals of Oncology.

A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer

L. Sequist, P. Fidias, R. Heist, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials

M. Socinski, L. Minasian, D. Lake, 2017, JAMA oncology.

Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma

D. Christiani, R. Heist, R. Zhai, 2012, International journal of cancer.

MET amplification (amp) as a resistance mechanism to osimertinib.

C. Azzoli, L. Sequist, A. Shaw, 2017 .

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

M. Hidalgo, R. Heist, A. Schram, 2018, British Journal of Cancer.

Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.

D. Christiani, R. Heist, R. Zhai, 2014, Cancer epidemiology.

ALK Resistance Mutations in ALK-Positive Lung Cancer

Lauren L. Ritterhouse, S. Digumarthy, A. Iafrate, 2016 .

Safety and clinical activity of atezolizumab plus erlotinib in patients with non-small-cell lung cancer

C. Rudin, S. Gettinger, R. Heist, 2023, ESMO open.

Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

J. Baselga, R. Heist, G. Shapiro, 2013 .

Circulating Tumor DNA Identifies EGFR Coamplification as a Mechanism of Resistance to Crizotinib in a Patient with Advanced MET-Amplified Lung Adenocarcinoma.

S. Digumarthy, M. Mino‐Kenudson, A. Shaw, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

PD-(L)1 Inhibitors and CTLA-4 Inhibitors: Rationale for Combinations and Recent Data in Non-Small Cell Lung Cancer

R. Heist, 2015 .

Alliance A071701: Genomically guided treatment trial in brain metastases.

S. Carter, P. Brown, A. Iafrate, 2020 .

SNaPshot genotyping of non-small cell lung cancers (NSCLC) in clinical practice.

A. Iafrate, M. Mino‐Kenudson, L. Sequist, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II clinical trial of ganetespib (STA-9090) in previously treated patients with advanced esophagogastric cancers.

W. Goessling, R. Heist, P. Enzinger, 2013 .

Phase II trial of oxaliplatin, pemetrexed, and bevacizumab in previously-treated advanced non-small cell lung cancer (NSCLC)

L. Sequist, R. Heist, J. Temel, 2007 .

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

C. Dooms, Toshio Shimizu, R. Heist, 2022, Cancer Research.

OA12.02 Updated Antitumor Activity of Crizotinib in Patients with MET Exon 14-Altered Advanced Non-Small Cell Lung Cancer

S. C. Wang, A. Drilon, R. Heist, 2018, Journal of Thoracic Oncology.

New Therapies on the Horizon.

R. Heist, Alissa J Cooper, 2023, Hematology/oncology clinics of North America.

Variation in mechanisms of acquired resistance (AR) among EGFR-mutant NSCLC patients with more than one post-resistant biopsy.

S. Digumarthy, M. Mino‐Kenudson, L. Sequist, 2014 .

Effect of early palliative care on chemotherapy utilization and end-of-life care in patients with metastatic non-small cell lung cancer (NSCLC).

R. Heist, J. Temel, J. Greer, 2011, Journal of Clinical Oncology.

Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Abstract CT082: Capmatinib inMETex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRYmono-1study, including efficacy in patients (pts) with brain metastases (BM)

H. Groen, E. Smit, R. Heist, 2020 .

Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion (METAmp/Ex14∆).

R. Heist, E. Felip, A. Navarro, 2020 .

Capmatinib in patients with METex14-mutated or high-level MET-amplified advanced non–small-cell lung cancer (NSCLC): results from cohort 6 of the phase 2 GEOMETRY mono-1 study.

H. Groen, A. Mansfield, E. Smit, 2020 .

Heterogeneity and Variation in Resistance Mechanisms Among 223 Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Patients With > 1 Post-Resistance Biopsy.

S. Digumarthy, C. Azzoli, M. Mino‐Kenudson, 2017, International journal of radiation oncology, biology, physics.

Activity of AUY922 in NSCLC patients with EGFR exon 20 insertions.

L. Sequist, J. Engelman, A. Shaw, 2015 .

Epidermal growth factor A61G gene polymorphism, gastroesophageal reflux disease and esophageal adenocarcinoma risk.

D. Christiani, R. Heist, R. Zhai, 2009, Carcinogenesis.

Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.

Xihong Lin, N. Nishioka, D. Christiani, 2008, Carcinogenesis.

KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation

P. Jänne, S. Ou, R. Heist, 2020 .

First-Line Systemic Therapy for Non-Small Cell Lung Cancer.

R. Heist, 2017, Hematology/oncology clinics of North America.

Abstract LB-147: Combination of the MEK inhibitor, pimasertib (MSC1936369B), and the PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors: Results of a phase Ib dose-escalation trial.

J. Baselga, R. Heist, G. Shapiro, 2013 .

A multicenter phase II trial of adjuvant erlotinib in patients with resected non-small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR): Toxicity evaluation.

C. Azzoli, P. Jänne, J. Neal, 2010 .

OA 17.02 Updated Efficacy Results From the BIRCH Study: First-Line Atezolizumab Therapy in PD-L1–Selected Patients With Advanced NSCLC

R. Heist, F. Shepherd, L. Paz-Ares, 2017 .

Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study

D. Schadendorf, C. Dooms, P. Ascierto, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pembrolizumab in brain metastases of diverse histologies: phase 2 trial results

A. Giobbie-Hurder, P. Wen, D. Cahill, 2023, Nature Medicine.

Capmatinib in patients with high-level MET-amplified advanced non–small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study.

H. Groen, T. Overbeck, E. Smit, 2020 .

Co-mutations and KRAS G12C inhibitor efficacy in advanced NSCLC.

S. Digumarthy, G. Scagliotti, L. Landi, 2023, Cancer discovery.

Phase I/II study of combined BCL-XL and MEK inhibition with navitoclax (N) and trametinib (T) in KRAS or NRAS mutant advanced solid tumours

Jeffrey W. Clark, R. Sullivan, K. Flaherty, 2019, Annals of Oncology.

Abstract CT048: Phase 1/2 study of olaparib tablets and temozolomide in patients with small cell lung cancer (SCLC) following failure of prior chemotherapy

C. Azzoli, D. Haber, L. Sequist, 2017 .

Debio 1347, an oral FGFR inhibitor: Results from a first-in-human, phase I dose-escalation study in patients with FGFR genomically activated advanced solid tumors.

K. Flaherty, J. Baselga, M. Voss, 2017 .

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation.

S. Ou, R. Heist, J. Christensen, 2022, Journal of Clinical Oncology.

M. Spitz, J. Minna, S. Lippman, 2014, Clinical pharmacology and therapeutics.

Impact on Disease Development, Genomic Location and Biological Function of Copy Number Alterations in Non-Small Cell Lung Cancer

Xihong Lin, L. Chirieac, D. Christiani, 2011, PloS one.

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

Toshio Shimizu, R. Heist, Melissa L. Johnson, 2021 .

Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy

R. Heist, T. Lynch, W. Urba, 2008 .

Efficacy and Tolerability of ALK/MET Combinations in Patients With ALK-Rearranged Lung Cancer With Acquired MET Amplification: A Retrospective Analysis

S. Digumarthy, L. Sequist, R. Heist, 2023, JTO clinical and research reports.

Phase I single dose, two-period and two-sequence cross-over trial to evaluate the relative bioavailability of two oral pimasertib formulations in advanced cancer patients

R. Heist, A. Naing, D. Mahadevan, 2017, Cancer Chemotherapy and Pharmacology.

Association between Polymorphisms in Cancer-Related Genes and Early Onset of

D. Christiani, R. Heist, R. Zhai, 2011 .

NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.

B. Loo, R. Heist, J. Hayman, 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer

M. Socinski, P. Watson, R. Heist, 2015 .

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.

R. Heist, W. Edenfield, C. Li, 2016 .

MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC

C. Rudin, S. Gettinger, R. Heist, 2018, Journal of Thoracic Oncology.

P47.05 A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)

R. Heist, K. Yoh, A. Spira, 2021, Journal of Thoracic Oncology.

Structural and functional vascular dysfunction within brain metastases is linked to pembrolizumab inefficacy

Praveer Singh, A. Giobbie-Hurder, Jayashree Kalpathy-Cramer, 2023, bioRxiv.

Improved Survival Outcomes in Patients With MET-Dysregulated Advanced NSCLC Treated With MET Inhibitors: Results of a Multinational Retrospective Chart Review.

A. Mansfield, J. Neal, R. Heist, 2023, Clinical lung cancer.

COVID-19 Infection in a Lung Cancer Patient Population: Incidence, Presentation and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

Coronavirus Disease 2019 Infection in a Patient Population with Lung Cancer: Incidence, Presentation, and Alternative Diagnostic Considerations

S. Digumarthy, L. Sequist, R. Heist, 2020, JTO Clinical and Research Reports.

MO01.04 Management of Selected Adverse Events With Capmatinib: Institutional Experiences From the GEOMETRY Mono-1 Trial

R. Heist, E. Garon, K. Goodwin, 2021 .

Polymorphisms in MicroRNAs Are Associated with Survival in Non–Small Cell Lung Cancer

Hongbing Shen, C. Amos, Zhibin Hu, 2014, Cancer Epidemiology, Biomarkers & Prevention.

Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.

S. Digumarthy, L. Sequist, J. Engelman, 2016, JAMA oncology.

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer.

A. Iafrate, M. Mino‐Kenudson, J. Engelman, 2018, Cancer discovery.

End-of-Life Care in Patients with Metastatic Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations.

L. Sequist, R. Heist, J. Temel, 2016, Journal of palliative medicine.

Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer

T. Choueiri, R. Heist, B. Rini, 2020 .

Safety of osimertinib plus chemotherapy in EGFR-mutant NSCLC.

L. Sequist, A. Shaw, R. Heist, 2018 .

513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study

G. Giaccone, F. Hodi, S. Gettinger, 2015 .

Leveraging epidemiology and clinical studies of cancer outcomes: recommendations and opportunities for translational research.

C. Ulrich, J. Cerhan, T. Sellers, 2013, Journal of the National Cancer Institute.

A Rapid Outcomes Ascertainment System Improves the Quality of Prognostic and Pharmacogenetic Outcomes from Observational Studies

D. Christiani, L. Sequist, P. Fidias, 2008, Cancer Epidemiology Biomarkers & Prevention.

Therapy of advanced metastatic lung cancer with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): Phase I/II clinical experience.

A. Bardia, R. Heist, W. Messersmith, 2015 .

Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.

Roman K. Thomas, M. Mino‐Kenudson, D. Haber, 2018, Cancer discovery.

Invasive adenocarcinoma of the lung is associated with the upper lung regions.

Raúl San José Estépar, G. Washko, E. Mark, 2014, Lung cancer.

Acquired Resistance to Crizotinib in NSCLC with MET Exon 14 Skipping

Jeffrey W. Clark, L. Sequist, J. Engelman, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genome-Wide Association Study of Prognosis in Advanced Non–Small Cell Lung Cancer Patients Receiving Platinum-Based Chemotherapy

Hongbing Shen, Yi Wang, Chen Wu, 2012, Clinical Cancer Research.

Acquired Resistance to Afatinib in EGFR-Mutant Lung Cancer

L. Sequist, A. Shaw, R. Heist, 2014 .

1322PBIOMARKERS ASSOCIATED WITH CLINICAL ACTIVITY OF PD-L1 BLOCKADE IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE I STUDY OF MPDL3280A.

S. Gettinger, R. Heist, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01

A. Tolcher, R. Heist, F. Meric-Bernstam, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Small cell lung cancer.

R. Heist, K. Gregory, A. Ganti, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

MA 02.10 Phase I Study of ABBV-399 (Telisotuzumab Vedotin) as Monotherapy and in Combination with Erlotinib in NSCLC

R. Heist, K. Kelly, D. Camidge, 2017 .